164 related articles for article (PubMed ID: 34694218)
1. Acquired von Willebrand syndrome in patients with monoclonal gammopathy of undetermined significance investigated using a mechanistic approach.
Galletta E; Galvanin F; Bertomoro A; Daidone V; Casonato A
Blood Transfus; 2023 Jan; 21(1):74-82. PubMed ID: 34694218
[TBL] [Abstract][Full Text] [Related]
2. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
3. Successful use of lenalidomide to treat refractory acquired von Willebrand disease associated with monoclonal gammopathy.
Green A; Shen YP; Nelson AT; Sarode R; Ibrahim IF; Cao J; Afraz S; Yates SG
Ann Hematol; 2022 Dec; 101(12):2627-2631. PubMed ID: 36194257
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy.
Lavin M; Brophy TM; Rawley O; O'Sullivan JM; Hayden PJ; Browne PV; Ryan K; O'Connell N; O'Donnell JS
J Thromb Haemost; 2016 Jun; 14(6):1200-5. PubMed ID: 26991062
[TBL] [Abstract][Full Text] [Related]
5. Von Willebrand disease type Vicenza: In search of a classification for the archetype of reduced von Willebrand factor survival.
Casonato A; Galletta E; Galvanin F; Daidone V
EJHaem; 2021 Aug; 2(3):340-348. PubMed ID: 35844701
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome.
Stufano F; Boscarino M; Bucciarelli P; Baronciani L; Maino A; Cozzi G; Peyvandi F
Semin Thromb Hemost; 2019 Feb; 45(1):36-42. PubMed ID: 29913537
[TBL] [Abstract][Full Text] [Related]
7. A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis.
Rauch A; Caron C; Vincent F; Jeanpierre E; Ternisien C; Boisseau P; Zawadzki C; Fressinaud E; Borel-Derlon A; Hermoire S; Paris C; Lavenu-Bombled C; Veyradier A; Ung A; Vincentelli A; van Belle E; Lenting PJ; Goudemand J; Susen S
Thromb Haemost; 2016 May; 115(5):950-9. PubMed ID: 26791163
[TBL] [Abstract][Full Text] [Related]
8. Successful Perioperative Management of Orthotopic Cardiac Transplantation in a Pediatric Patient With Concurrent Congenital von Willebrand Disease and Acquired von Willebrand Syndrome Using Recombinant von Willebrand Factor.
Batsuli G; Zimowski KL; Carroll R; White MH; Woods GM; Meeks SL; Sidonio RF
J Cardiothorac Vasc Anesth; 2022 Mar; 36(3):724-727. PubMed ID: 33618961
[TBL] [Abstract][Full Text] [Related]
9. Different organization of von Willebrand factor oligomers in type-2A and -2B von Willebrand disease variants: effects of DDAVP infusion and protease inhibitors.
Casonato A; Pontara E; Bertomoro A; Dannhauser D; Secchiero S; Zaninotto M; Girolami A
Ann Hematol; 1995 Oct; 71(4):189-94. PubMed ID: 7578526
[TBL] [Abstract][Full Text] [Related]
10. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z
Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
[TBL] [Abstract][Full Text] [Related]
11. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
12. Differences in von Willebrand factor function in type 2A von Willebrand disease and left ventricular assist device-induced acquired von Willebrand syndrome.
Deconinck S; Tersteeg C; Bailleul E; Delrue L; Vandeputte N; Pareyn I; Itzhar-Baikian N; Deckmyn H; De Meyer SF; Vanderheyden M; Vanhoorelbeke K
Res Pract Thromb Haemost; 2018 Oct; 2(4):762-766. PubMed ID: 30397685
[TBL] [Abstract][Full Text] [Related]
13. A Mechanistic Model to Quantify von Willebrand Factor Release, Survival and Proteolysis in Patients with von Willebrand Disease.
Ferrari M; Galvanin F; Barolo M; Daidone V; Padrini R; Bezzo F; Casonato A
Thromb Haemost; 2018 Feb; 118(2):309-319. PubMed ID: 29378356
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and therapeutic management in a patient with type 2B-like acquired von Willebrand syndrome.
Karger R; Weippert-Kretschmer M; Budde U; Kretschmer V
Blood Coagul Fibrinolysis; 2011 Mar; 22(2):144-7. PubMed ID: 21178586
[TBL] [Abstract][Full Text] [Related]
15. Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias.
Dicke C; Schneppenheim S; Holstein K; Spath B; Bokemeyer C; Dittmer R; Budde U; Langer F
Ann Hematol; 2016 May; 95(6):945-57. PubMed ID: 27040683
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of inhibitors in acquired von Willebrand syndrome.
Mohri H; Motomura S; Kanamori H; Matsuzaki M; Watanabe S; Maruta A; Kodama F; Okubo T
Blood; 1998 May; 91(10):3623-9. PubMed ID: 9572997
[TBL] [Abstract][Full Text] [Related]
17. Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):577-88. PubMed ID: 16977568
[TBL] [Abstract][Full Text] [Related]
18. Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza.
Gézsi A; Budde U; Deák I; Nagy E; Mohl A; Schlammadinger A; Boda Z; Masszi T; Sadler JE; Bodó I
J Thromb Haemost; 2010 Jun; 8(6):1273-80. PubMed ID: 20088930
[TBL] [Abstract][Full Text] [Related]
19. Lack of multimer organization of von Willebrand factor in an acquired von Willebrand syndrome.
Casonato A; Pontara E; Doria A; Bertomoro A; Cattini MG; Gambari PF; Girolami A
Br J Haematol; 2002 Mar; 116(4):899-904. PubMed ID: 11886398
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Von Willebrand Factor Multimer Structure in Patients With Severe Aortic Stenosis.
Kellermair J; Ott HW; Spannagl M; Tomasits J; Kammler J; Blessberger H; Reiter C; Steinwender C
Clin Appl Thromb Hemost; 2018 Apr; 24(3):496-501. PubMed ID: 29202604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
